Young children may qualify for a COVID-19 VACCINE this fall, a top Pfizer executive noted plans to ask for emergency approval for the use of its vaccine in children ages 5 to 11 in September or October.
Dr. Alejandra Gurtman, vice president of clinical vaccine research and development at Pfizer, appeared with representatives from other major drug manufacturers to discuss the data and timelines behind the pediatric clinical trials on Thursday at a Johns Hopkins University-University of Washington. virtual symposium.
The PVizer vaccine COVID-19 is now approved for use in individuals aged 12 and over.
“With this data, we feel very comfortable moving with age,” said Gurtman, who spoke on trials involving participants aged 6 months to 11 years.
The tests involved a so-called dose-release technique to safely determine the appropriate dose for each age group. The company previously announced it selects the lowest doses of VACCINE for children younger than 11 than the number given to shot recipients aged 12 and over. For children aged 5-11 the vaccine will be given at a 10 microgram (and) dose level, while children 5 to 6 months will receive a 3 and dose level.
Gurtman said Pfizer began later -stage trials for all three age groups, with studies done in the U.S., Poland, Spain and Finland. He noted plans to vaccinate 4,500 participants with two doses spaced 21 days apart. – READ MORE
Listen to the insightful Thomas Paine Podcast Below –